0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > TGF-beta 1

TGF-beta 1

Brief Information

Name:Transforming growth factor beta 1
Target Synonym:Latency-Associated Peptide,IBDIMDE,Transforming Growth Factor beta1,Prepro-Transforming Growth Factor Beta-1,TGF-Beta-1,Transforming Growth Factor, Beta 1,CED,TGFB,DPD1,TGFB1,Transforming Growth Factor Beta-1 Proprotein,Camurati-Engelmann Disease,LAP,TGFbeta,Transforming Growth Factor Beta 1,Diaphyseal Dysplasia 1, Progressive,TGF-Beta1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:19
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Por estado del producto :
Por categoría de producto :
Por especies :
Por etiqueta :
Cat. No. Especies Descripción del producto Estructura Pureza Característica
TG1-M8218 Mouse / Rat Biotinylated Mouse / Rat TGF-Beta 1 / TGFB1 Protein, Avitag™
TG1-M8218-structure
TG1-M5218 Mouse / Rat Mouse / Rat TGF-Beta 1 / TGFB1 Protein, Tag Free
TG1-M5218-structure
TG1-M5218-sds
TG1-H4212 Human Human TGF-Beta 1 / TGFB1 Protein, premium grade
TG1-H4212-structure
TG1-H4212-sds
ACRO Quality

Part of Bioactivity data

TG1-H4212-Cell-based assay
 TGF-beta 1 CELL

Human TGFB1, premium grade (Cat. No. TG1-H4212) inhibits the Human IL-4, premium grade (Cat. No. IL4-H4218) dependent proliferation the TF-1 cells. The specific activity of Human TGFβ1, premium grade is > 8.00ⅹ10^6 IU/mg, which is calibrated against transforming growth factor β1 (NIBSC code: 89/514) (QC tested).

TG1-H4212-ELISA
 TGF-beta 1 ELISA

Immobilized Human TGFB1, premium grade (Cat. No. TG1-H4212) at 0.2 μg/mL (100 μL/well) can bind Human TGFBR2, Fc Tag (Cat. No. TG2-H5252) with a linear range of 0.2-2.5 ng/mL (QC tested).

TG1-M5218-ELISA
 TGF-beta 1 ELISA

Immobilized Mouse / Rat TGFB1, Tag Free (Cat. No. TG1-M5218) at 0.2 μg/mL (100 μL/well) can bind Biotinylated Mouse TGF-beta RII, His,Avitag (Cat. No. TG2-M82H5) with a linear range of 1-20 ng/mL (QC tested).

Customer Reviews

Synonym Name

CEDLAP,TGF-beta 1,TGFB1,DPD1,TGF-beta-1,TGFB

Background

Transforming growth factor beta 1 ( TGFB1) is also known as TGF-β1, CED, DPD1, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis.  The TGFB1 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB1 protein is found throughout the body and plays a role in development before birth, the formation of blood vessels, the regulation of muscle tissue and body fat development, wound healing, and immune system function. TGFB1 is particularly abundant in tissues that make up the skeleton, where it helps regulate bone growth, and in the intricate lattice that forms in the spaces between cells (the extracellular matrix). Within cells, this protein is turned off (inactive) until it receives a chemical signal to become active. TGFB1 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages. Most immune cells (or leukocytes) secrete TGFB1. TGFB1 has been shown to interact with TGF beta receptor 1, LTBP1, YWHAE, EIF3I  and Decorin.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
AVID-200 AVID-200; BMS-986416; AVID-200 DP Phase 1 Clinical Formation Biologics Corp Solid tumours; Polycythemia Vera; Primary Myelofibrosis; Scleroderma, Diffuse; Thrombocythemia, Essential Details
Nicousamide XLF-III-43 Phase 2 Clinical Institue Of Materia Medica Chinese Academy Of Medical Science Hypertensive nephropathy; Diabetic Nephropathies Details
Cotsiranib STP-705LU; STP-705LV; STP-705; STP-705L Phase 2 Clinical Sirnaomics, Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd Liver Neoplasms; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Cholangiocarcinoma; Obesity, Abdominal; Keloid; Carcinoma, Hepatocellular; Cicatrix, Hypertrophic Details
Meflonidone hydrochloride Phase 2 Clinical Guangzhou Nanxin Pharma Co Ltd, Central South University Diabetes Mellitus, Type 2; Diabetic Nephropathies Details
Yinfenidone Hydrochloride HEC-585; HEC-00000585 Phase 2 Clinical Hec Pharm Co Ltd Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial Details
Dalutrafusp alfa AGEN-1423; GS-1423 Phase 2 Clinical Gilead Inc, Agenus Inc Solid tumours; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal Details
Linavonkibart SRK-181 Phase 1 Clinical Scholar Rock Neoplasms Details
JYB-1907 JYB-1907 Phase 1 Clinical Jiangxi Jemincare Group Co Ltd Solid tumours Details
Nisevokitug NIS-793 Phase 3 Clinical Xoma Corp Kidney Neoplasms; Liver Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Breast Neoplasms; Colorectal Neoplasms; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Adenocarcinoma Details
PXS-64 PXS-64 Phase 1 Clinical Pharmaxis Ltd Multiple Sclerosis Details
SB-01 (Spine Biopharma) SB-01 Phase 3 Clinical Spine BioPharma Inc Intervertebral disc disease; Low Back Pain Details
ZSP-1603 ZSP-1603 Phase 2 Clinical Wuxi Apptec Co Ltd, Guangdong Zhongsheng Pharmaceutical Co Ltd Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Charis-1000 Charis-1000; C 1K; C1K Phase 1 Clinical Ensol Biosciences Breast Neoplasms Details
Vactosertib TEW-7197; EW-7197; NOV-1301 Phase 3 Clinical Medpacto Inc Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Myelodysplastic Syndromes; Carcinoma, Transitional Cell; Myeloproliferative Disorders; Osteosarcoma; Colorectal Neoplasms; Urologic Neoplasms; Esophageal adenocarcinoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
STP-707 STP-707 Phase 1 Clinical Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd Solid tumours; Liver Neoplasms; Liver Cirrhosis; Pulmonary Fibrosis; Cholangitis, Sclerosing Details
Fluorofenidone AKF-PD Phase 2 Clinical Dierepharma HK Ltd, Hainan Haiyao Co Ltd, Central South University Liver Cirrhosis Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Gallbladder Neoplasms; Sarcoma; Vulvar Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Microsatellite Instability; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Oropharyngeal Neoplasms; Colorectal Neoplasms; Thymus Neoplasms; Penile Neoplasms; Adenomyoepithelioma; Lung Neoplasms; Lymphoma; Brain metastases; Urogenital Neoplasms; Thymoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Sarcoma, Kaposi; Esthesioneuroblastoma, Olfactory; Biliary Tract Neoplasms; Solid tumours; Hematologic Neoplasms; Intestinal Neoplasms; Vaginal Neoplasms; Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Stomach Neoplasms; Carcinoma; Carcinoma, Renal Cell; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Colonic Neoplasms; Carcinoma, Transitional Cell; Papillomavirus Infections; Nose Neoplasms; Ganglioglioma; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Re Details
Livmoniplimab ABBV151; MGH-8; ARGX-115; AGRX-115 Phase 3 Clinical Argenx Se, Abbvie Inc Solid tumours; Carcinoma, Hepatocellular Details
YL-13027 YL-13027 Phase 2 Clinical YL-Pharma Solid tumours Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje